story of the week
Mirvetuximab Soravtansine for FRα-Positive Platinum-Resistant Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
N. Engl. J. Med 2023 Dec 07;389(23)2162-2174, KN Moore, A Angelergues, GE Konecny, Y García, S Banerjee, D Lorusso, JY Lee, JW Moroney, N Colombo, A Roszak, J Tromp, T Myers, JW Lee, M Beiner, CM Cosgrove, D Cibula, LP Martin, R Sabatier, J Buscema, P Estévez-García, L Coffman, S Nicum, LR Duska, S Pignata, F Gálvez, Y Wang, M Method, A Berkenblit, D Bello Roufai, T Van GorpFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.